GIVAX

GIVAX is an early-stage biotech company pioneering a novel oral vaccine platform based on engineered rotavirus vectors. Its core technology repurposes the established safety and mucosal immunogenicity of existing rotavirus vaccines to express antigens from other GI pathogens, starting with norovirus. The company's lead programs target a significant unmet need in pediatric and adult populations, with the potential to address a multi-billion dollar global disease burden. GIVAX is privately held and appears to be in the pre-clinical or early research stage of development.

A novel oral vaccine platform using engineered rotavirus as a replicating vector to express exogenous antigens from other gastrointestinal pathogens, designed to induce mucosal immunity.

The norovirus vaccine space is competitive, with several candidates from companies like Vaxart (oral tablet), HilleVax (injected VLP), and others in clinical trials. GIVAX differentiates with its oral rotavirus vector approach, aiming for combined pediatric protection and strong gut immunity, but is at an earlier stage of development.